The stock of Neurocrine Biosciences, Inc. (NBIX) has gone down by -2.61% for the week, with a -17.24% drop in the past month and a -9.84% drop in the past quarter. The volatility ratio for the week is 4.52%, and the volatility levels for the past 30 days are 2.84% for NBIX. The simple moving average for the past 20 days is -15.76% for NBIX’s stock, with a -11.27% simple moving average for the past 200 days.
Is It Worth Investing in Neurocrine Biosciences, Inc. (NASDAQ: NBIX) Right Now?
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) has a price-to-earnings ratio of 36.41x that is above its average ratio. Additionally, the 36-month beta value for NBIX is 0.38. There are mixed opinions on the stock, with 8 analysts rating it as a “buy,” 5 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for NBIX is 98.73M and currently, short sellers hold a 2.31% ratio of that float. The average trading volume of NBIX on September 05, 2024 was 865.26K shares.
NBIX) stock’s latest price update
Neurocrine Biosciences, Inc. (NASDAQ: NBIX)’s stock price has dropped by -1.64 in relation to previous closing price of 122.54. Nevertheless, the company has seen a loss of -2.61% in its stock price over the last five trading days. fool.com reported 2024-08-30 that The biotech released the results of phase 2 clinical trial of its investigational schizophrenia drug. One of the four doses clearly performed well.
Analysts’ Opinion of NBIX
Many brokerage firms have already submitted their reports for NBIX stocks, with Piper Sandler repeating the rating for NBIX by listing it as a “Overweight.” The predicted price for NBIX in the upcoming period, according to Piper Sandler is $159 based on the research report published on August 29, 2024 of the current year 2024.
Wells Fargo, on the other hand, stated in their research note that they expect to see NBIX reach a price target of $170, previously predicting the price at $140. The rating they have provided for NBIX stocks is “Overweight” according to the report published on April 24th, 2024.
Citigroup gave a rating of “Neutral” to NBIX, setting the target price at $127 in the report published on December 13th of the previous year.
NBIX Trading at -15.98% from the 50-Day Moving Average
After a stumble in the market that brought NBIX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -23.71% of loss for the given period.
Volatility was left at 2.84%, however, over the last 30 days, the volatility rate increased by 4.52%, as shares sank -16.17% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -10.55% lower at present.
During the last 5 trading sessions, NBIX fell by -2.37%, which changed the moving average for the period of 200-days by +11.09% in comparison to the 20-day moving average, which settled at $141.91. In addition, Neurocrine Biosciences, Inc. saw -8.52% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at NBIX starting from RASTETTER WILLIAM H, who sale 14,250 shares at the price of $146.69 back on Aug 15 ’24. After this action, RASTETTER WILLIAM H now owns 37,491 shares of Neurocrine Biosciences, Inc., valued at $2,090,332 using the latest closing price.
LYONS GARY A, the Director of Neurocrine Biosciences, Inc., sale 11,570 shares at $150.43 during a trade that took place back on Aug 13 ’24, which means that LYONS GARY A is holding 119,047 shares at $1,740,450 based on the most recent closing price.
Stock Fundamentals for NBIX
Current profitability levels for the company are sitting at:
- 0.26 for the present operating margin
- 0.98 for the gross margin
The net margin for Neurocrine Biosciences, Inc. stands at 0.16. The total capital return value is set at 0.19. Equity return is now at value 15.55, with 11.46 for asset returns.
Based on Neurocrine Biosciences, Inc. (NBIX), the company’s capital structure generated 0.1 points at debt to capital in total, while cash flow to debt ratio is standing at 1.82. The debt to equity ratio resting at 0.12. The interest coverage ratio of the stock is 165.06.
Currently, EBITDA for the company is 416.1 million with net debt to EBITDA at 0.27. When we switch over and look at the enterprise to sales, we see a ratio of 5.81. The receivables turnover for the company is 4.53for trailing twelve months and the total asset turnover is 0.64. The liquidity ratio also appears to be rather interesting for investors as it stands at 4.19.
Conclusion
In conclusion, Neurocrine Biosciences, Inc. (NBIX) has seen bad performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
